Bone density in myasthenia gravis patients receiving long-term prednisolone therapy

详细信息	查看全文 | 推荐本文 |

• 作者：Wakata ; Nobuo ; Nemoto ; Hiroshi ; Sugimoto ; Hideki ; Nomoto ; Nobuatu ; Konno ; Shingo ; Hayashi ; Norihide ; et. al.
• 关键词：Osteoporosis ; Bone density ; Deoxypyridinoline ; DX method ; CXD method ; Myasthenia gravis
• 刊名：Clinical Neurology and Neurosurgery
• 出版年：2004
• 期刊代码：60_03038467
• 类别：med
• 出版时间：March, 2004
• 卷：106
• 期：2
• 页码：139-141
• 文件大小：44.5 K

摘要

Osteoporosis is an adverse effect of prednisolone therapy, although no study has been conducted on myasthenia gravis patients receiving high-dose prednisolone. We measured bone density in 36 patients (26 females and 10 males) who had undergone long-term prednisolone administration, and found a decrease in bone density in 31%of female patients and osteoporosis in only 11.5%(three cases). This frequency is lower than the presumptive rate of the general population in Japan (22.6%). No osteoporosis was detected in male patients. In conclusion, prednisolone-treated patients with myasthenia gravis have an acceptable risk of bone loss if prophylactic medication is administered.